UNSPSC 51294413: Vanoxerine

This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90X28IKH43. European Medicines Agency schedules Vanoxerine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00023MIG. Vanoxerine generally arises in the molecular formula C28H32F2N2O. The term VANOXERINE is an International Non-Proprietary Name or INN. VANOXERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule vanoxerine under HS 29335995 and SITC 51576. As of Q4 2014, VANOXERINE remains the US FDA Preferred Term for this commodity. Vanoxerine bears US NLM identifiers UMLS ID C0164200 and NCI Concept Code C81084. SMILES: Fc1ccc(C(OCCN2CCN(CC2)CCCc2ccccc2)c2ccc(F)cc2)cc1.

UNSPSC 51294413 Vanoxone, a Commodity code, covers pharmaceutical products that state and local governments procure through health departments, county health systems, and multistate cooperative purchasing alliances to support community health initiatives, emergency response, and public health programs. Recent solicitations show state and local buyers acquiring naloxone and related pharmaceutical products for opioid response, generic multi-source pharmaceuticals and over-the-counter products for distributed health facilities, and exploring direct-to-manufacturer prescription programs to improve fulfillment efficiency and cost management. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), which aggregate demand across multiple participating state and local jurisdictions. The work spans supply chain management, product compliance with FDA and Drug Supply Chain Security Act requirements, distribution logistics including quarterly or regular deliveries to specified health facilities, and increasingly sophisticated pricing negotiation models outside traditional pharmacy benefit manager arrangements.

Activity appears concentrated in Florida, Texas, and Minnesota, with MMCAP's model extending to participating states including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023), an IFB seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026), a request for information on direct-to-manufacturer prescription capabilities to inform future formal procurement strategy; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026), an RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with evaluation weighted heavily on price competitiveness (75 percent). Vendors must maintain significant insurance coverage including commercial general liability and comply with cGMP certification and DSCSA requirements.